Roohi Peter, senior reporter at Labiotech, spoke with leaders from across the Nordic and global biotech ecosystem at NLS Days 2026, where epigenetics, cell therapy and next‑generation oncology platforms dominated the conversation.

Among them were Sten Sörensen, CEO of Cereno Scientific, who outlined why the company is pushing HDAC inhibition to the forefront of cardiopulmonary innovation, and CuraCell Oncology, the Swedish cell‑therapy developer advancing next‑generation TIL therapies for solid tumours. Together, they reflected a meeting shaped by scientific depth, investor appetite and a clear shift toward mechanisms capable of modifying disease biology rather than simply managing symptoms.

Sörensen described how Cereno’s repurposed HDAC inhibitor is now showing promise in pulmonary arterial hypertension through epigenetic modulation. CuraCell, meanwhile, highlighted progress on its CytoPLY™ platform and its ambition to make personalised TIL therapies faster, more potent and scalable for high‑prevalence cancers. Both companies emphasised the importance of collaboration as they move toward pivotal clinical milestones.

To read how Cereno Scientific, CuraCell and other innovators are shaping the Nordic biotech landscape, access the full article here.